Biomarkers for early prostate cancer detection

Minerva Urologica e Nefrologica

Volumn 60, Issue 1, 2008, Pages 51-60

  Margreiter, M ^a   Stangelberger, A ^a   Valimberti, E ^a   Herwig, R ^a   Djavan, B ^a,b   Marberger, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE   (Austria)

Author keywords

Biological markers; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

BIOLOGICAL MARKER; GLANDULAR KALLIKREIN 2; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TISSUE KALLIKREIN;

BIOTECHNOLOGY; CANCER DIAGNOSIS; EARLY CANCER; FOLLOW UP; HUMAN; PROSTATE CANCER; REVIEW;

HUMANS; MALE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL;

EID: 43949143180     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics 2003. CA Cancer J Clin 2003;53:5-26.
2. WHO. World Health report [Internet]. [2000] Available from: http://www.who.org/whr.
3. The American Cancer Society. Cancer Facts & Figures. Atlanta, GA: American Cancer Society, Inc.;1998. p.14-5, 20-4.
4. Riegman PH, Vlietstra RJ, Klaassen P, van der Korput JA, Geurts van Kessel A, Romijn JC et al. The prostate-specific antigen gene and the human glandular kallikrein-1 gene are tandemly located on chromosome 19. FEBS Lett 1989;247:123-6.
5. Boccon-Gibod L. Rising PSA with negative biopsy. Eur Urol 2001;40(Suppl. 2):3-8.
6. Brawer MK, Cheli CD, Neaman IE, Goldblatt J, Smith C, Schwartz MK et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000;163:1476-80.
7. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ et al. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
8. Bretton PR. Prostate specific antigen and digital rectal examination in screening for prostate cancer: a community based study. South Med J 1994;87:720-3.
9. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ confined prostate cancer is increased through prostate specific antigen based screening. JAMA 1993;270:948-54.
10. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997;277:1452-5.
11. Catalona WJ, Partin AW, Finlay JA, Chan DW, Rittenhouse HG, Wolfert RL et al. Use of percentage of free prostate specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 1999;54:220-4.
12. Djavan B, Zlotta A, Kratzik C, Remzi M, Seitz C, Schulman CC et al. PSA, PSA density, PSA density of transitional zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology 1999;54:517-22.
13. Babaian RJ, Fritsche H, Ayala A, Bhadkamkar V, Johnston DA, Naccarato W et al. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL. Urology 2000;56:1000-6.
14. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A et al. Use of percentage of free prostate specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-7.
15. Djavan B, Zlotta AR, Byttebier G, Shariat S, Omar M, Schulman CC et al. Prostate specific antigen density of the transitional zone for early detection of prostate cancer. J Urol 1998;160:411-9.
16. Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1051 patients. J Urol 2000;163:1144-9.
17. Piironen T, Pettersson K, Suonpaa M, Stenman UH, Oesterling JE, Lovgren T et al. In vitro stability of free prostate specific antigen (PSA) and prostate specific antigen (PSA) complexed to alpha1-antichymotrypsin in blood samples. Urology 1996;48(Suppl):81-7.
18. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
19. Babaian RJ, Fritsche HA, Evans RB. Prostate specific antigen and prostate gland volume: correlation and clinical application. J Clin Lab Anal 1990;4:135-7.
20. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992;147:817-21.
21. Morote J, Raventos CX, Lorente JA, Lopez-Pacios MA, Encabo G, de Torres I et al. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng/mL. J Urol 1997;158:502-4.
22. Kuriyama M, Uno H, Watanabe H, Yamanaka H, Saito Y, Shida K. Determination of reference values for total PSA, F/T and PSAD according to prostatic volume in Japanese prostate cancer patients with slightly elevated serum PSA levels. Jpn J Clin Oncol 1999;29:617-22.
23. Reissigl A, Horninger W, Fink K, Klocker H, Bartsch G. Prostate cancer screening in the county of Tyrol, Austria: experience and results. Cancer 1997;80:1818-29.
24. Borer JG, Sherman J, Solomon MC, Plawker MW, Macchia RJ. Age specific prostate specific antigen reference ranges: population specific. J Urol 1998;159:444-8.
25. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993;71:2031-40.
26. Carter HB, Morrell CH, Pearson JD, Brant LJ, Plato CC, Metter EJ et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992;52:3323-8.
27. Ornstein DK, Smith DS, Rao GS, Basler JW, Ratliff TL, Catalona WJ. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol 1997;157:2179-82.
28. Nixon RG, Wener MH, Smith KM, Parson RE, Blase AB, Brawer MK. Day to day changes in free and total PSA: significance of biological variation. Prostate Cancer Prostatic Dis 1997;1:90-6.
29. Porter JR, Hayward R, Brawer MK. The significance of short term PSA change in men undergoing ultrasound guided prostate biopsy. J Urol 1994;151(Suppl):293.
30. Nixon RG, Meyer GE, Blase AB, Gold MH, Brawer MK. Comparison of three investigational assays for the free form of prostate specific antigen. J Urol 1998;160:420-5.
31. Brawer MK, Meyer GE, Letran JL, Bankson DD, Morris DL, Yeung KK et al. Measurement of complexed PSA improves the specificity for early detection of prostate cancer. Urology 1998;52:372-8.
32. Okegawa T, Noda H, Nutahara K, Higashihara E. Comparison of two investigational assays for the complexed prostate specific antigen in total prostate specific antigen between 4.0 and 10.0 ng/mL. Urology 2000;55:700-4.
33. Mitchell ID, Croal BL, Dickie A, Cohen NP, Ross I. A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. J Urol 2001;165:49-53.
34. Miller MC, O'Dowd GJ, Partin AW, Veltri RW. Contemporary use of complexed PSA and calculated per cent free PSA for early detection of prostate cancer: impact of changing demographics. Urology 2001;57:1105-11.
35. Djavan B, Remzi M, Zlotta AR, Ravery V, Hammerer P, Reissigl A et al. Complexed prostate specific antigen, complexed prostate specific antigen density of total and transitional zone, complexed/total prostate specific antigen ratio, free-to-total prostate specific antigen ratio, density of total and transition zone prostate specific antigen: results of the prospective multicenter European trial. Urology 2002;60:4-9.
36. Maeda H, Arai Y, Aoki Y, Okubo K, Okada T, Maekawa S. Complexed prostate specific antigen and its volume indexes in the detection of prostate cancer. Urology 1999;54:225-8.
37. Okihara K, Cheli CD, Partin AW, Fritche HA, Chan DW, Sokoll LJ et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen, and their ratio in detecting prostate cancer. J Urol 2002;167:2017-23.
38. Stamey TA, Yemoto CE. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transitional zone volume. J Urol 2000;163:119-24.
39. Partin AW, Brawer MK, Bartsch G, Horninger W, Taneja SS, Lepor H et al. Complexed prostate specific antigen improves the specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 2003;170:1787-91.
40. Horninger W, Cheli CD, Babaian RJ, Fritsche HA, Lepor H, Taneja SS, Childs S, Stamey TA, Sokoll LJ, Chan DW, Brawer MK, Partin AW, Bartsch G. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology. 2002 Oct;60(4 Suppl 1):31-5.
41. Figueroa JA, De Raad S, Tadlock L, Speights VO, Rinehart JJ. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J Urol 1998;159:1379-83.
42. Thrasher JB, Tennant MK, Twomey PA, Hansberry KL, Wettlaufer JN, Plymate SR. Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: clinical correlations. J Urol 1996;155:999-1003.
43. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
44. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000;92:1910-7.
45. Lamharzi N, Schally AV, Koppan M, Groot K. Growth hormone releasing antagonist Mz 5-15 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the level and mRNA expression of insulin-like growth factor-2. Proc Natl Acad Sci USA 1998;95:8864-8.
46. Schedlich LJ, Benetts B, Morris BJ. Primary structure of a human glandular kallikrein gene. DNA 1987;6:429-37.
47. Lovgren J, Piironen T, Overmo C, Dowell B, Karp M, Pettersson K et al. Production of recombinant PSA and HK2 and analysis of their immunologic cross-reactivity. Biochem Biophys Res Commun 1995;213:888-95.
48. Piironen T, Lovgren J, Karp M, Eerola R, Lundwall A, Dowell B et al. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hk2) in serum. Clin Chem 1996;42:1034-41.
49. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Saeid MS et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 1999;53:939-44.
50. Partin AW, Catalona WJ, Smith DS. Use of human glandular kallikrein 2 for detection of prostate cancer: preliminary analysis. Urology 1999;54:839-45.
51. Becker C, Piironen T, Pettersson K, Hugosson J, Lilja H. Clinical value of human glandular kallikrein 2 and free and total prostate specific antigen in serum form a population of men with prostate specific antigen levels 3 ng/mL or greater. Urology 2000;55:694-9.
52. Nurmikko P, Vaisanen V, Piironen T, Lindgren S, Lilja H, Pettersson K. Production and characterization of novel anti-prostate specific antigen (PSA) monoclonal antibodies that do not detect the internally cleaved Lys145-Lys146 inactive PSA. Clin Chem 2000;46:1610-18.
53. Nurmikko P, Pettersson K, Piironen T, Hugosson J, Lilja H. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin Chem 2001;47:1415-23.
54. Steuber T, Nurmikko P, Haese A, Pettersson K, Graefen M, Hammerer P et al. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. J Urol 2002;168:1917-22.
55. Linton HJ, Marks LS, Millar LS, Knott CL, Rittenhouse HG, Mikolajczyk SD. Benign prostate specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 2003;49:253-9.
56. Mikolajczyk SD, Millar LS, Marker KM, Wang TJ, Rittenhouse HG, Marks LS et al. Seminal plasma contains "BPSA", a molecular form of prostate specific antigen that is associated with benign prostatic hyperplasia. Prostate 2000;45:271-6.
57. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Marks LS, Song W et al. A precursor form of prostate specific antigen is highly elevated in prostate cancer compared with benign transitional zone prostate tissue. Cancer Res 2000;60:756-9.
58. Mikolajczyk SD, Grauer LS, Millar LS, Hill TM, Kumar A, Rittenhouse HG et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997;50:710-4.
59. Mikolajczyk SD, Marker KM, Millar LS, Kumar A, Saedi MS, Payne JK et al. A truncated precursor form of prostate specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001;61:6958-63.
60. Peter J, Unverzagt C, Krogh TN, Vorm O, Hoesel W. Identification of precursor forms of free prostate specific antigen in serum of prostate cancer patients by immunosorption and spectrometry. Cancer Res 2001;61:957-62.
61. Mikolaiczyk SD, Rittenhouse HG. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med 2003;52:86-91.
62. Sokoll LJ, Chan DW, Mikolajczyk SD. Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/mL total PSA range: preliminary analysis. Urology 2002;59:261-5.
63. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Amirkhan A et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2.4-4 ng/mL. J Urol 2003;170:2181-5.
64. Herwig R, Horninger W, Rehder P, Klocker H, Ramoner R, Thurnher M et al. Ability of PSA-positive circulating macrophages to detect prostate cancer. Prostate 2005;62:290-8.
65. Herwig R, Pelzer A, Horninger W, Rehder P, Klocker H, Ramoner R et al. Measurement of intracellular versus extracellular prostate-specific antigen levels in peripheral macrophages: a new approach to noninvasive diagnosis of prostate cancer. Clin Prostate Cancer 2004;3:184-8.
66. Clements JA, Rhode P, Allen V, Hyland VJ, Samaratunga ML, Tilley WD et al. Molecular detection of prostate cells in ejaculate and urethral washings of men with suspected prostate cancer. J Urol 1999;161:1337-43.
67. Muller M, Goessl C, Krause H, Miller K. Molecular diagnostics in urologic oncology. Detection of nuclic acids in urine samples. Urologe A 2003;42:660-8.
68. Harden SV, Guo Z, Epstein JL, Sidransky D. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostatic adenocarcinoma. J Urol 2003;169:1138-42.
69. Goessl C, Muller M, Heicappell R, Krause H, Straub B, SchraderM et al. DANN-based detection of prostate cancer in urine after prostatic massage. Urology 2001;58:335-8.
70. Cairns P, Esteller M, Hermann JG, Schoenberg M, Jeronimo C, Sanchez-Cespedes M et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation Clin Cancer Res 2001;7:2727-30.
71. Meid FH, Gygi CM, Leisinger HJ, Bosman FT, Benhattar J. The use of telomerase activity fort he detection of prostate cancer cells after prostatic massage. J Uol 2001;165:1802-5.
72. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-9.
73. Verhaegh GW, van Bokhoven A, Smit F, Schalken JA, Bussemakers MJ. Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene. J Biol Chem 2000;275:37496-503.
74. Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of polymerase chain reaction. Science 1992;257:967-71.
75. Liang P, Pardee AB. Differential display: a general protocol. Mol Biotechnol 1998;10:261-7.
76. Martin KJ, Pardee AB. Principles of differential display. Methods Enzymol 1999;303:234-58.
77. Zhang JS, Duncan EL, Chang AC, Reddel RR. Differential display of mRNA. Mol Biotechnol 1998;10:155-65.
78. Schalken JA, Hesseis D, Verhaegh G. New targets for therapy in prostate cancer: Differential display code 3 (DD3PCA3), a highly prostate cancer-specific gene. Urology 2003;62(Suppl):34-43.
79. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B et al. DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15.
80. Tinzl M, Djavan B, Marberger M. uPM3 test: a new molecular assay detecting prostate cancer in urine samples; a new future perspective. J Urol 2003;169(4 Suppl):121. Abstract 468.
81. Saad F, Aprikian AG, Dessureault J, et al. Multicenter study of the uPM3 test, a new molecular urine assay to detect prostate cancer. J Urol 2003;169(4 Suppl):121. Abstract 469.
82. Jeronimo C, Nomoto S, Caballero OL, Usadel H, Henrique R, Varzim G et al. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 2001;20:5195-8.
83. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW et al. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumours. Cancer Res 2002;62:2695-8.
84. Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004;64:311-6.
85. Hessels D, Klein-Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-16.
86. Wang H, Xi X, Kong X, Huang G, Ge G. The expression and significance of survivin mRNA in urinary bladder carcinomas. J Cancer Res Clin Oncol 2004;130:487-90.
87. Lwaleed BA, Francis JL, Chisholm M. Urinary tissue factor levels in patients with bladder and prostate cancer. Eur J Surg Oncol 2000;26:44-9.
88. Stoeber K, Swinn R, Prevost AT, de Clive-Lowe P, Halsall I, Dilworth SM et al. Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments. J Natl Cancer Inst 2002;94:1071-9.
89. Tanaka M, Tanaka T, Matsuzaki S, Seto Y, Matsuda T, Komori K et al. Rapid and quantitative detection of human septin family Bradeion as a practical diagnostic method of colorectal and urologic cancers. Med Sci Monit 2003;9:MT61-8.
90. Lombardo ME, Hudson PB. Preliminary evaluation of 5_-reductase type 2 in urine as potential marker for prostate disease. Steroids 1997;62:682-5.